RMTI earnings analysis
What we found in RMTI's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The provided extract is limited to Part II and does not include the income statement, balance sheet, cash flow statement, segment results, or MD&A; therefore, revenue, margins, EPS, liquidity, and free-cash-flow trends cannot be assessed from the filing text supplied. Management reported effective disclosure controls as of June 30, 2026 and no material changes to internal controls. No material changes were reported to the risk factors from the 2025 Form 10-K, and no quantitative guidance was provided.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Disclosure controls effective
- Management concluded that disclosure controls and procedures were effective as of June 30, 2026.
- No material control changes
- The company reported no changes in internal control over financial reporting during the period covered by the report that materially affected, or were reasonably likely to materially affect, those controls.
- CEO adopts 10b5-1 sale plan
- A Rule 10b5-1 trading arrangement adopted by CEO Mark Strobeck covers 12,250 shares, with a stated duration from October 1, 2026 through July 3, 2028, subject to earlier completion.
- Market-risk disclosure exemption
- As a Smaller Reporting Company, Rockwell Medical is not required to provide the market-risk disclosures under Item 3 pursuant to Regulation S-K Section 229.305.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Existing 10-K risks remain applicable
- The company states that there have been no material changes to the risk factors in its 2025 Form 10-K, so the existing risk profile remains applicable through June 30, 2026.
- Routine legal proceedings
- Rockwell says it may be involved in routine legal proceedings, cannot predict their final disposition, and does not expect resolution to have a material effect on operations or consolidated financial statements in the period resolved.
- Planned insider share sales
- The CEO’s Rule 10b5-1 arrangement provides for the sale of 12,250 shares beginning October 1, 2026 and potentially continuing through July 3, 2028, which could create incremental equity-sale pressure.
What they said about what is next.
The provided 10-Q text contains no quantitative revenue or EPS outlook. Numeric guidance is therefore not provided in this filing.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 7, 2026
- Rockwell Medical experienced a decline in revenue and EPS for Q1 2026, reporting $17.3 million in revenue, down 8% from $18.9 million in Q1 2025, with an EPS of -$0.04. The company emphasized an operational pivot…
- 10-K · March 26, 2026
- Rockwell Medical (RMTI) remained focused on its hemodialysis concentrates business in 2025 but experienced a meaningful revenue decline versus 2024 while making product and customer gains. Management added a…
- 10-Q · August 14, 2025
- Rockwell Medical reported Q2 net sales of $16,071 (in thousands) and a GAAP diluted loss per share of $(0.05). Revenue declined materially vs. both the prior quarter and prior year, compressing gross margin to 15.6% and…
- 10-K · March 20, 2025
- Rockwell Medical (RMTI) has refocused on its hemodialysis concentrates business (dialysate concentrates accounted for 100% of 2024 revenue) and expanded distribution via multiple agreements and the July 2023 Evoqua…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing RMTI makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever